Detecting Contradictory Evidence on Drug-Disease Associations at Scale
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Contradictory claims about drug efficacy across randomized controlled trials (RCTs) complicate evidence-based medicine, yet existing automated methods classify isolated sentence pairs and do not explain why studies disagree. We present DrugCon, a large language model (LLM)-based framework that extracts study conclusions from RCT abstracts, links these claims when they concern the same drug-disease association, detects contradictions with counterfactual reasoning, and explains them using a taxonomy of ten study-level factors such as population, dosage, and outcome measures. Applying DrugCon to 224,756 RCT abstracts, we built DrugCon-Bench, an exhaustively annotated benchmark of 542 contradictory claim pairs from 819 abstracts. Most contradictions involve more than one study-level factor (75.5%). The most common are differences in outcome measures (64.0%), populations (51.3%), and dosage or exposure duration (35.6%). DrugCon achieves an F1 score of 0.744 for contradiction detection, outperforming rule-based, supervised, and natural language inference baselines, and an F1 of 0.482 for identifying explanatory study factors. DrugCon enables scalable and explainable analysis of contradictory clinical evidence.